---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104592"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:19:32.873879+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Whitehawk Q2 net loss $52.6M; cash $177.2M, runway to 2028

## Summary
- Net loss of $52.6M vs $14.6M Q2 2024; includes $38M upfront payment under Wuxi ADC deal.
- Cash, equivalents & short-term investments $177.2M at June 30, 2025 (vs $47.2M Dec 31, 2024).
- IND filings on track: HWK-007 and HWK-016 by year-end 2025; HWK-206 by mid-2026.
- Cash anticipated to fund operations into 2028, enabling initial clinical data readouts.

## SEC filing metadata
- accession: 0000950170-25-104592
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000095017025104592/0000950170-25-104592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000095017025104592/whwk-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104592
- JSON: https://secwatch.observer/filing/0000950170-25-104592.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.